The European Medicines Agency (EMA) has approved Leqembi, a groundbreaking treatment for Alzheimer’s disease, for patients not yet in advanced stages. Initially blocked in July due to concerns over severe side effects, the drug is now recommended for those at…

The European Medicines Agency (EMA) has partially approved Leqembi (lecanemab) for patients with mild cognitive decline or mild dementia due to Alzheimer’s disease, reversing a prior rejection. The treatment is now authorized for those with a lower risk of adverse…